Amfetamine use disorder

References

Key articles

Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003026.Full text  Abstract

Roll JM, Petry NM, Stitzer ML, et al. Contingency for the treatment of methamphetamine use disorder. Am J Psychiatry. 2006 Nov;163(11):1993-9. Abstract

Shoptaw SJ, Kao U, Heinzerling K, et al. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003021.Full text  Abstract

Sheridan J, Bennett S, Coggan C, et al. Injury with methamphetamine use: a review of the literature. Harm Reduct J. 2006 Mar 29;3:14.Full text  Abstract

Reference articles

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

2. Rosenson J, Smollin C, Sporer KA, et al. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2007 Feb;49(2):164-71. Abstract

3. United Nations Office on Drugs and Crime. World drug report 2018. June 2018 [internet publication].Full text

4. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017. 2017 [internet publication].Full text

5. Rehm J, Room R, van den Brink W, et al. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol. 2005 Aug;15(4):377-88. Abstract

6. National Institute on Drug Abuse. National survey of drug use and health [internet publication].Full text

7. Sung YH, Cho SC, Hwang J, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007 Apr 17;88(1):28-35. Abstract

8. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001 Aug;36(1):1-22. Abstract

9. Hendrickson RG, Horowitz BZ, Norton RL. "Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing". Clin Toxicol (Phila). 2006;44(4):379-82. Abstract

10. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006 Jan;81(1):77-84. Abstract

11. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006 Aug;26(8):1148-56. Abstract

12. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010 Aug;48(7):675-94. Abstract

13. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb;120(2):165-71. Abstract

14. Chin KM, Channick RN, Rubin LJ. Is meth-amphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63. Abstract

15. Goodchild JH, Donaldson M. Methamphetamine abuse and dentistry: a review of the literature and presentation of a clinical case. Quintessence Int. 2007 Jul-Aug;38(7):583-90. Abstract

16. U.S Preventive Services Task Force. Final recommendation statement. Unhealthy drug use: screening. June 2020 [internet publication].Full text

17. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry. 2008 Mar;69(3):358-67. Abstract

18. Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med. 1997 Sep;4(3):130-5. Abstract

19. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003026.Full text  Abstract

20. Rawson R, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002 Sep;23(2):145-50. Abstract

21. Roll JM, Petry NM, Stitzer ML, et al. Contingency for the treatment of methamphetamine use disorder. Am J Psychiatry. 2006 Nov;163(11):1993-9. Abstract

22. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006 Nov;83(6):1151-7.Full text  Abstract

23. Sherman SG, Sutcliffe C, Srirojn B, et al. Evaluation of a peer network intervention trial among young methamphetamine users in Chiang Mai, Thailand. Soc Sci Med. 2009 Jan;68(1):69-79.Full text  Abstract

24. Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014 Oct 1;143:11-21.Full text  Abstract

25. Lee NK, Rawson RA, Lee NK, et al. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008 May;27(3):309-17.Full text  Abstract

26. D'Souza MS, Markon A. Neural substrates of psychostimulant withdrawal-induced anhedonia. Curr Top Behav Neurosci. 2010;3:119-78. Abstract

27. Karila L, Weinstein A, Aubin HJ, et al. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010 Jun;69(6):578-92.Full text  Abstract

28. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract. 2011 Dec;24(6):541-50. Abstract

29. Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Oct 15;85(1):12-8. Abstract

30. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008 Apr;33(5):1162-70. Abstract

31. McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012 May;18(5):414-8. Abstract

32. Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Dec 1;85(3):177-84. Abstract

33. Shoptaw SJ, Kao U, Heinzerling K, et al. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003021.Full text  Abstract

34. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33. Abstract

35. Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010 Jan;105(1):146-54. Abstract

36. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489-500.Full text  Abstract

37. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Jul;108(7):1279-86. Abstract

38. Solhi H, Jamilian HR, Kazemifar AM, et al. Methylphenidate vs. resperidone in treatment of methamphetamine dependence: a clinical trial. Saudi Pharm J. 2014 Jul;22(3):191-4.Full text  Abstract

39. Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015 Sep;40(10):2347-56.Full text  Abstract

40. Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013 Nov;38(12):2427-38.Full text  Abstract

41. Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014 May;7(3):363-74.Full text  Abstract

42. De La Garza R 2nd, Newton TF, Haile CN, et al. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141-6. Abstract

43. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct;108(1):76-85. Abstract

44. Calabria BD, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav. 2010 Aug;35(8):741-9. Abstract

45. Turnipseed SD, Richards JR, Kirk D, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003 May;24(4):369-73. Abstract

46. Mortelmans LJM, Bogaerts PJM, Hellemans S, et al. Spontaneous pneumomediastinum and myocarditis following ecstasy use: a case report. Eur J Emerg Med. 2005 Feb;12(1):36-8. Abstract

47. Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci. 1999 Jan;44(1):23-6. Abstract

48. Rejali D, Glen P, Odom N. Pneumomediastinum following ecstasy (methylenedioxymethamphetamine, MDMA) ingestion in two people at the same "rave". J Laryngol Otol. 2002 Jan;116(1):75-6. Abstract

49. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON. 2005 Jul;(16):vii-III1. Abstract

50. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009 Aug;17(4):291-4. Abstract

51. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010 Aug 7;376(9739):458-74. Abstract

52. Silber BY, Croft RJ, Papafotiou K, et al. The effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl). 2006 Aug;187(2):154-69. Abstract

53. Sheridan J, Bennett S, Coggan C, et al. Injury with methamphetamine use: a review of the literature. Harm Reduct J. 2006 Mar 29;3:14.Full text  Abstract

Use of this content is subject to our disclaimer